Biomarin Pharmaceuticals
(BMRN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 426,859 | 167,645 | 141,561 | -64,080 | 854,029 |
| Depreciation Amortization | 88,081 | 95,158 | 105,012 | 113,194 | 105,739 |
| Income taxes - deferred | 56,096 | -44,981 | -52,087 | -15,608 | -889,993 |
| Accounts receivable | -57,909 | -190,435 | -82,033 | 65,574 | -59,035 |
| Other Working Capital | -216,396 | -336,539 | -96,383 | 66,034 | -224,935 |
| Other Operating Activity | 276,110 | 468,411 | 159,832 | 139,422 | 299,560 |
| Operating Cash Flow | $572,841 | $159,259 | $175,902 | $304,536 | $85,365 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 222,768 | -3,633 | 8,186 | -246,094 | 26,171 |
| PPE Investments | -75,424 | -96,691 | -17,634 | -95,578 | -114,312 |
| Purchase Sale Intangibles | -11,994 | -10,920 | -10,581 | -23,647 | 43,952 |
| Other Investing Activity | -10,853 | -10,920 | -10,581 | -24,641 | 34,520 |
| Investing Cash Flow | $136,491 | $-111,244 | $-20,029 | $-366,313 | $-53,621 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | N/A | N/A | N/A | N/A | 585,752 |
| Debt Repayment | -494,987 | N/A | N/A | -3,039 | -381,909 |
| Common Stock Issued | 49,277 | 69,353 | 69,333 | 49,194 | 71,913 |
| Common Stock Repurchased | N/A | N/A | N/A | N/A | -50,000 |
| Other Financing Activity | -80,737 | -88,080 | -87,983 | -46,203 | -44,638 |
| Financing Cash Flow | $-526,447 | $-18,727 | $-18,650 | $-48 | $181,118 |
| Exchange Rate Effect | 4,830 | 1,308 | 32 | -57 | -1,150 |
| Beginning Cash Position | 755,127 | 724,531 | 587,276 | 649,158 | 437,446 |
| End Cash Position | 942,842 | 755,127 | 724,531 | 587,276 | 649,158 |
| Net Cash Flow | $187,715 | $30,596 | $137,255 | $-61,882 | $211,712 |
| Free Cash Flow | |||||
| Operating Cash Flow | 572,841 | 159,259 | 175,902 | 304,536 | 85,365 |
| Capital Expenditure | -85,424 | -96,691 | -120,959 | -95,578 | -114,312 |
| Free Cash Flow | 487,417 | 62,568 | 54,943 | 208,958 | -28,947 |